PMID- 22135499
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20121002
LR  - 20240412
IS  - 1178-7007 (Electronic)
IS  - 1178-7007 (Linking)
VI  - 4
DP  - 2011
TI  - Management of diabetes across the course of disease: minimizing 
      obesity-associated complications.
PG  - 353-69
LID - 10.2147/DMSO.S24022 [doi]
AB  - Obesity increases the risk for developing type 2 diabetes mellitus (T2DM) and 
      this in turn correlates with an elevated probability of long-term diabetes 
      complications once diabetes is established. Interventions aimed at lowering 
      weight via changes in diet and lifestyle have repeatedly been shown to improve 
      glycemic control in patients with T2DM and even to reverse early disease. Weight 
      gain, a potential side effect of treatment for patients with T2DM, is also an 
      important concern, and it has been noted that weight increases associated with 
      antidiabetes therapy may blunt cardiovascular risk reductions achieved by 
      decreasing blood glucose. Among older agents, metformin and acarbose have the 
      lowest risk for weight gain, while sulfonylureas, meglitinides, and 
      thiazolidinediones are all associated with weight increases. Clinical trial 
      results have also consistently demonstrated that treatment with glucagon-like 
      peptide-1 receptor agonists and amylin lowers weight, and that dipeptidyl 
      peptidase-4 inhibitors are weight neutral in patients with T2DM. Conventional 
      human insulin formulations are known to increase weight in patients with T2DM. 
      However, some insulin analogs, particularly insulin detemir, have lower liability 
      for this adverse event. The use of both pharmacologic and surgical therapies 
      aimed at treating obesity rather than lowering blood glucose have the potential 
      to improve glycemic control and even resolve T2DM in some patients.
FAU - Apovian, Caroline M
AU  - Apovian CM
AD  - Medicine and Pediatrics, Boston University School of Medicine; Nutrition and 
      Weight Management Center; and Section of Endocrinology, Diabetes and Nutrition, 
      Department of Medicine, Boston Medical Center, Boston, MA, USA.
LA  - eng
PT  - Journal Article
DEP - 20111012
PL  - New Zealand
TA  - Diabetes Metab Syndr Obes
JT  - Diabetes, metabolic syndrome and obesity : targets and therapy
JID - 101515585
PMC - PMC3224657
OTO - NOTNLM
OT  - bariatric
OT  - diabetes
OT  - incretin
OT  - insulin
OT  - obesity
OT  - oral antidiabetes agents
EDAT- 2011/12/03 06:00
MHDA- 2011/12/03 06:01
PMCR- 2011/10/12
CRDT- 2011/12/03 06:00
PHST- 2011/12/03 06:00 [entrez]
PHST- 2011/12/03 06:00 [pubmed]
PHST- 2011/12/03 06:01 [medline]
PHST- 2011/10/12 00:00 [pmc-release]
AID - dmso-4-353 [pii]
AID - 10.2147/DMSO.S24022 [doi]
PST - ppublish
SO  - Diabetes Metab Syndr Obes. 2011;4:353-69. doi: 10.2147/DMSO.S24022. Epub 2011 Oct 
      12.